

Index

- Abnormal Involuntary Movements Scale, 93, 111
- accelerometry, 191
- acetylcholine antagonists; *see also* anticholinergic drugs; cholinergic mechanisms
 diagnostic use, 79, 145
 mechanism of action, 236–7
 neuroleptic-induced depression, 53
- ACTeRS scale, 39
- actigraphy, 194–5
 akathisia movement variability, 139–40
 overview, 194–5
 and restless legs syndrome, 306
- activating tasks
 acute akathisia suppression, 133–4
 tardive/chronic akathisia response, 169
- acute akathisia, 349
 aetiology, 210–22
 anticholinergic drugs in, 253–9
 benzodiazepine treatment, 271–5
 β -adrenergic antagonists in, 259–71
 characteristic symptoms, 13–14, 121–6
 demographic factors, 118–20
 diagnostic criteria, 68–74, 80
 differential diagnosis, 144–51
 dopaminergic hypothesis, 227–32
 epidemiology, 88–105
 extrapyramidal side-effects relationship, 141–3
 motor features, 67, 130–44
 natural history, 179–80
 and neuroleptic dosage, 89, 92, 94
 objective features, 130–44
 pathogenesis, 222–43, 351–2
 model, 240–3
 and psychosis exacerbation, 125–7
 restless legs syndrome distinction, 316–21
 signs and symptoms, 121–6, 130–3
- as tardive dyskinesia risk factor, 143–4
- treatment, 252–79, 352–3
 guidelines, 278–80
 typology, 13–15
 variability, 138–41
 violence association, 128
- acute persistent akathisia
 diagnostic criteria, 83
 onset factors, 158
 typology, 14, 83
 validity as diagnosis, 87
- adolescence, akathisia epidemiology, 114–15
- adrenergic receptors
 and acute akathisia, 232–4
 supersensitivity hypothesis, 233–4, 248
 and tardive akathisia, 248
- affective disorders, and restlessness, 21–2
- age factors
 acute akathisia, 118–19
 akathisia remission, 180
 restless legs syndrome, 297
 tardive/chronic akathisia, 156–7
- aggression, and acute akathisia, 128
- agitation; *see also* agitation in dementia; agitation of depression
 definition, 29
 differential diagnosis, 146–7
 drug treatment, 43–5
 measurement scales, 39–42
 in restless legs syndrome, 303–4
- agitation in dementia, 25–6
 behavioural aspects, 25–6
 drug treatment, 43–4
 factor analysis, 31
 measurement, 40–1
 operational definition, 30–1
 time of day factors, 31–2

- agitation of depression
 differential diagnosis, 147
 endogenous vs nonendogenous depression,
 29–30
 measurement scales, 39–40
 and melancholia, 18, 21, 29
 akathisia due to general medical condition,
 181–7, 289, 350–1
 Akathisia Questionnaire and Examination,
 198–200
 Akathisia Rating Scale (Barnes), 200–1,
 363–5
 Akathisia Rating Scale (Bartels), 197–8
 Akathisia Rating Scale (Friis), 198–9
 Akathisie (Haskovec), 355–9
 alcohol, as risk factor, 220
 alcohol withdrawal, 25
 α -adrenergic drugs
 acute akathisia treatment, 271
 mechanism of action, 233–4
 α -adrenergic receptors
 akathisia mechanism, 232–4
 supersensitivity hypothesis, 233–4
 alpha-motoneurons, 324
 alprazolam, agitation treatment, 45
 Alzheimer's disease, restlessness, 26
 amantadine, 254–6, 275–6
 ambulatory monitoring, *see* actigraphy
 amisulpiride, 97, 100
 amitriptyline
 acute akathisia cause, 103
 acute akathisia treatment, 277
 restless legs syndrome treatment, 339–40
 amoxapine
 acute akathisia cause, 98, 104
 dopamine antagonist properties, 24
 amperozide, 101
 amphetamines
 mechanism of action, 242
 and psychomotor agitation, 24
 Analogue Scale for Akathisia, 198–9
 animal models, 222–7
 akathisia, 222–7
 dopaminergic system, 224–6
 neuroleptic-induced dysphoria, 57–9
 pharmacological isomorphism principle,
 223–4
 serotonergic function, 226–7
 subjective akathisia, 224
 symptom similarity principle, 222–3
 anosognosia, 165
 anticholinergic drugs; *see also* acetylcholine
 antagonists
 acute akathisia treatment, 253–9, 278–80
 guidelines, 278–80
 mechanism of action, 236–7
 pharmacokinetics, 258–9
 prophylactic use, 257
 anticonvulsants, akathisia role, 98, 104
 antidepressant-induced akathisia
 epidemiology, 98, 103–4
 mechanism of action, 213, 234
 antimuscarinic drugs, 25
 antipsychotic drugs, *see* neuroleptic dosage;
 neuroleptic-induced akathisia
 anxiety
 akathisia interaction, 141
 differential diagnosis, 146
 fidgetiness relationship, 34
 and neuroleptic-induced dysphoria, 49–50
 and restless legs syndrome, 301
 anxiety disorders, 22
 apomorphine challenge, 247, 286
 arm movements
 acute akathisia sign, 131–3, 162
 and tardive/chronic akathisia, 160, 162,
 166, 168
 arousal, in nocturnal myoclonus, 305
 assessment, akathisia, 188–209, 351
 atenolol, 233, 267–9, 272, 285
 athetoid movements, 150
 atropine, and restlessness, 25
 attention-deficit hyperactivity disorder
 clinical manifestations, 32
 measurement, 38–9
 prevalence, 23
 and restlessness, 22–3, 32
 atypical neuroleptics; *see also* clozapine
 acute akathisia role, 96–101
 dopamine receptor affinities, 229
 autism, and hyperactivity, 23
 autonomic arousal, nocturnal myoclonus, 305
Awakenings (Sacks), 16, 182
 baclofen, 339–40
 ballismus, 186, 239
 Barnes Akathisia Rating Scale, 200–1, 363–5
 basal ganglia, 240
 Beard, George, 4
 Behavioral Observation Schedule, 37
 Behavioural Problem Checklist, 42
 behavioural symptoms

- acute akathisia, 128–34
- fidgetiness, 32–4, 131–3
- tardive/chronic akathisia, 162–5
- benzamide, 99–101
- benhexol, 258
- benzodiazepines
 - acute akathisia treatment, 271–5
 - GABA mechanisms, 238
 - jitteriness treatment, 35
 - in restless legs syndrome, 330, 333–5
 - in restlessness/agitation, 45
 - tardive akathisia treatment, 249, 286–7
- benzotropine
 - acute akathisia treatment, 253–9
 - guidelines, 279
 - pharmacokinetics, 258–9
 - propranolol comparative efficacy, 266–7
 - relative potency, 257–8
 - tardive akathisia treatment, 283–4
- benzotropine challenge
 - cholinergic mechanisms, 237
 - diagnostic utility, 79
 - symptom improvement, 256
 - tardive akathisia response, 283–4
- β -adrenergic antagonists
 - acute akathisia treatment, 259–72, 278–80
 - guidelines, 278–80
 - in agitation and aggression, 45
 - diagnostic use, 145
 - mechanism of action, 233–4
 - pharmacological characteristics, 268
 - tardive akathisia treatment, 285
- β_1 -antagonists
 - acute akathisia treatment, 269–70, 272
 - pharmacological characteristics, 268
- β_2 -antagonists
 - acute akathisia treatment, 270, 272
 - pharmacological characteristics, 268
- betaxolol, 268, 270, 272
- biceps femoris muscle, 304
- Bing, R., 5–6
- Bing–Sicard akathisia, 15, 182–4
- biperiden
 - acute akathisia treatment, 253, 256, 258
 - pharmacokinetics, 258–9
 - relative potency, 258
- biperiden challenge, 79
- Blessed Dementia Scale, 401
- blood levels, neuroleptics, 11
- body rocking, *see* rocking movements
- brain trauma, and restlessness, 26–7, 184–5
- Brief Psychiatric Rating Scale, 93
- bromocriptine
 - in restless legs syndrome, 329–30, 332
 - and tardive akathisia, 248
- bupirone
 - acute akathisia role, 98, 103
 - myoclonus cause, case report, 136
- butyrophenones, 10
- caffeine, 24
- calcium channel antagonists
 - acute akathisia cause, 98, 104–5
 - mechanism of action, 213–14
 - restless legs syndrome treatment, 338, 340
- catatonia
 - measurement, 38
 - motor symptom cluster, 22
- catatonic schizophrenia, restlessness, 22
- catecholamine-depleting drugs, 285–6
- Child Behavior Checklist, 38–9
- childhood disorders, and restlessness, 22–3
- children, akathisia epidemiology, 114–15
- chlorpromazine, receptor affinities, 213
- cholinergic antagonists, *see* anticholinergic drugs
- cholinergic mechanisms, 236–8
- acute akathisia pathogenesis, 236–8, 241–2
- dopaminergic interactions, 237–8
- polysomnographic studies, 237
- tardive akathisia pathogenesis, 249
- choreoathetoid movements
 - in chronic akathisia, 171–2
 - differential diagnosis, 150
 - tardive dyskinesia symptom, 14, 171
- choreic movements, chronic akathisia, 171–2
- Chouinard Extrapyramidal Rating Scale, 197–8
- chronic akathisia, 152–80, 349–50
 - acute akathisia relationship, 143–4
 - aetiology, 243–6
 - age factors, 156–7, 180
 - behavioural analogues, 162–5
 - characteristic symptoms, 13–14
 - clinical characteristics, 13–14, 158–80
 - differential diagnosis, 178–9
 - epidemiology, 106–12
 - motor features, 165–72, 176–8
 - natural history, 179–80
 - objective (motor) features, 165–72, 176–8
 - onset, 157–8
 - operational definition, 78–9

- chronic akathisia (*cont.*)
 pathogenesis, 247–50, 351–2
 reduced distress in, 159, 162
 research diagnostic criteria, 81
 risk, 179–80
 tardive akathisia relationship, 154–5
 tardive dyskinesia overlap, 170–5
 treatment, 279–88, 352–3
 guidelines, 284, 288
 typology, 13–15, 249–50
 variability, 169–70
- chronic schizophrenia, akathisia distress, 176–8
- cinnarizine, 98, 105
- circadian rhythm, 325
- clomipramine, 103
- clonazepam
 in acute akathisia, 274–5
 in restless legs syndrome, 330, 333–5
 guidelines, 341
 in tardive akathisia, 286, 288
- clonidine
 in acute akathisia, 271
 in restless legs syndrome, 336, 340
 in tardive akathisia, 285
- clozapine
 akathisia cause, 96–7, 99
 receptor affinities, 213
 tardive akathisia treatment, 282
- cocaine, and psychomotor agitation, 24
- codeine
 in chronic akathisia, 287
 in restless legs syndrome, 334, 336–7
- cognitive impairment
 akathisia role, elderly, 130
 and tardive akathisia, 246
- cogwheel rigidity, 79
- Cohen–Mansfield Agitation Inventory, 31, 42
- computerized tomography, 187
- conduct disorder, and restlessness, 23
- conversion reaction, 148
- cortical–striatal–thalamic circuits, 240–2
- cypheptadine, 98, 103
- D₁ receptor, 212, 230
- D_{1A} receptor, 230
- D₂ receptor
 acute akathisia pathogenesis, 228–9
 and iron deficiency, 218
 neuroleptic drug mechanism, 212
 positron emission tomography, 228
- D₃ receptor, 229–30
- D₄ receptor, 212, 229–30
- D₅/D_{1B} receptor, 230
- deep sleep, 307
- defecation, *see* emotion-induced defecation model
- delirium
 causes, 19–20
 psychomotor hyperactivity, 25
- delirium tremens, 25
- dementia
 agitated behaviours, 30–2, 40–1, 43–4
 restlessness, 25–6
- Dementia Mood Assessment Scale, 41
- depot fluphenazine, 121
- depression; *see also* agitation of depression
 akathisia epidemiology, 120
 neuroleptics as cause, 52–3
 restlessness, 21–2, 28–30
 and tardive akathisia, 246
- derealization, 49–50
- desipramine, 35
- diabetes mellitus, 221
- diagnostic criteria
 acute akathisia, 68–77, 80, 83
 sensitivity and specificity, 68–74, 76–7
 chronic akathisia, 81
 receiver operating characteristic analysis, 68–74, 76–7
 restless legs syndrome, 311
 tardive akathisia, 74, 76–7, 81–2
 withdrawal akathisia, 81
- diazepam
 acute akathisia treatment, 273–4
 restless legs syndrome treatment, 330, 335
 tardive akathisia treatment, 286
- diazepam challenge, 273
- diltiazem, 98, 105
- DiMascio Reversible Extrapyramidal Symptom Scale, 113
- diphenhydramine, 257–8
- discontinuation treatment strategy, 281
- disinhibition, and akathisia, 129
- L-dopa
 akathisia-like syndrome cause, 182–4
 restless legs syndrome treatment, 327–9, 331–2
 guidelines, 341
- dopamine antagonists, 23–4
- dopamine-depleting drugs, 283–6
- dopamine receptor supersensitivity, 247–8
- dopamine receptors; *see also* D₁ . . . D₄ receptors
 acute akathisia mechanism, 227–32

- neuroleptic affinities, 212–13, 230
- summary characteristics, subtypes, 230
- tardive akathisia mechanism, 247–8
- dopaminergic mechanisms
 - acute akathisia, 227–32, 240–3
 - model, 240–3
 - animal models, 224–6
 - Parkinson's disease, 184
 - restless legs syndrome, 323
 - tardive akathisia, 247–8
 - and ventral tegmental area syndrome, 224–6
- dosage factors, *see* neuroleptic dosage
- doxepin, 103
- drug compliance
 - akathisia role, 130
 - and neuroleptic-induced dysphoria, 49
- drug discontinuation strategy, 281
- drug dosage, *see* neuroleptic dosage
- drug-induced akathisia, *see* acute akathisia; chronic akathisia; tardive akathisia
- drug-induced parkinsonism
 - akathisia relationship, 16, 42
 - anticholinergic drug treatment, 257
 - and tremor, 137
- drug withdrawal, and restlessness, 25
- duration of neuroleptic treatment
 - as risk factor, 216, 217
 - and tardive akathisia, 158–9
- dysaesthetic dyskinesia, 314–15
- dyskinesias while awake, 302, 305
- dyskinetic movements, akathisia comparison, 67, 150, 172
- dysmentia, 164–5
- dysphoria, *see* neuroleptic-induced dysphoria

- Ekbom, K. A., 6–7
- Ekbom's syndrome, 16, 311; *see also* restless legs syndrome
- elbow rigidity, 142
- elderly
 - agitated behaviours, 30–2, 40–2
 - akathisia epidemiology, 116–17
 - restlessness, 25–6
 - sex differences in akathisia, 157
- electroconvulsive therapy
 - acute akathisia treatment, 278
 - tardive akathisia treatment, 287
- electroencephalography, 136
- electromyography, 193–4
 - akathisia variability, sleep, 140
 - methodology, 193–4
- nocturnal myoclonus, 136, 194
- restless legs syndrome, 302, 304–5, 312
- emotion-induced defecation model
 - advantages and disadvantages, 224
 - neuroleptic effects, 58–9, 224
 - serotonin effects, 227
- emotions, *see* subjective akathisia
- encephalitis lethargica, 181–2
- endogenous depression, agitation, 29–30
- endogenous opioids
 - akathisia mechanism, 238
 - restless legs syndrome, 323
- epidemiology
 - akathisia, 85–117, 348–9
 - restless legs syndrome, 296–7
- epoetin, 326
- erythromelalgia, 321
- esmolol, 268
- ethical issues, 289–91
- ethosuximide, 104
- Extrapyramidal Rating Scale (Chouinard), 197–8
- extrapyramidal side effects
 - acute akathisia overlap and differences, 141–3
 - anticholinergic drug treatment, 254, 257
 - in children and adolescents, 114
 - drug discontinuation study, 113
 - and neuroleptic clinical efficacy, 10–11
 - and neuroleptic-induced dysphoria, 54–5
 - pathophysiology, 176
 - tardive/chronic akathisia overlap, 175–6
 - as tardive dyskinesia risk factor, 144
- Extrapyramidal Side-Effects Rating Scale (Kabes), 198–9
- Extrapyramidal Symptom Scale (Simpson and Angus), 197, 199
- extraversion, and nervous habits, 34

- familial dysaesthetic syndromes, 308–9
- ferritin levels, 244, 326
- fever, and restless legs syndrome, 325
- fidgetiness
 - acute akathisia sign, 131–3
 - behavioural manifestations, 32–4, 131–3
 - definition, 29
 - measurement scales, 37–8
 - Parkinson's disease, 183–4
 - and personality, 33–4
 - and stress, 20–1
- Fidgeting Tendency Questionnaire, 37
- finger movements, acute akathisia, 136

- finger tapping task
 - involuntary movement suppression, 133
 - and tardive akathisia, 246
- flunarizine, 98, 105
- fluoxetine
 - acute akathisia role, 98, 102
 - akathisia mechanism of action, 235–6
 - restlessness association, 24
 - suicidal ideation cause, 130
- fluphenazine
 - plasma levels, 216
 - receptor affinities, 213
- fluphenazine decanoate
 - acute akathisia incidence, 92
 - akathisia onset, 121
- fluvoxamine, 103
- focal akathisia, 186
- folate supplementation, 327
- foot movements
 - acute akathisia, 136, 162, 168
 - tardive/chronic akathisia, 160–2, 166–8
 - and tremor, 137
- Forced Immobilization Test, 306
- frequency counts, 195
- Freyhan, F. A., 8, 10
- frontal cortex, 229–32, 240–2
- frustration, and restlessness, 20–1
- fusaric acid, 248, 287
- GABAergic mechanisms
 - akathisia, 238, 240–2, 249
 - restless legs syndrome, 324
- gamma-motoneurons, 324
- genetics, restless legs syndrome, 308–9
- geriatric populations, *see* elderly
- GERRI symptom scale, 41
- globus pallidus, 239, 241–2
- glucose intolerance, 221
- glutamatergic system, 238–9
- growing pains, 322
- haloperidol
 - acute akathisia incidence, 89, 90
 - dosage effects, 90
 - akathisia onset, 121
 - dopamine system effect, 232
 - plasma levels, 216
 - receptor affinities, 213
 - separation anxiety syndrome, 50–1
- haloperidol challenge, 89
- Hamilton Depression Scale, 39–40
- hand movements
 - acute akathisia sign, 131–3
 - chronic/tardive akathisia, 160, 162, 166, 168
- Haskovec, L., 3–4, 355–9
- head injury, and restlessness, 26–7, 184–5
- head movements, 166
- heat, and restless legs syndrome, 300–1
- hemiakathisia, 186
- hemiballismus, 186, 239
- heterocyclic antidepressants, 98, 103–4
- high-dosage neuroleptics, 90
- high-potency neuroleptics
 - D₂ receptor antagonism, 228
 - as risk factor, 214, 252–3
- Hillside Akathisia Scale, 198, 201–2, 366–8
- Hillside-LIJ scale, 198–9
- homicide, and akathisia, 12, 128–9
- 5HT syndrome, *see* serotonin syndrome
- 5HT₂ receptor, 235–6
- 5HT₂/D₂ receptor ratio, 235
- 5HT₃ receptor, 236
- Huntington's chorea
 - differential diagnosis, 178
 - pathophysiology, 239–40
- hydrophilic β -antagonists, 233, 267–9, 272
- hyperactivity, *see* attention-deficit hyperactivity disorder
 - and restlessness, 18, 23, 29
 - and serotonin syndrome, 226
 - ventral tegmental area role, 224–5
- hypoglycemia, and restlessness, 27
- hysteria, differential diagnosis, 148, 179
- ICI 118,551, 268, 270, 272
- ICI 204,636, 101
- idiopathic parkinsonism, 15
- idiopathic restless legs syndrome, 310–11
- imipramine, and jitteriness, 34
- impatience musculaire, 7
- impulse control, 128–9
- incidence
 - acute akathisia, 88–105
 - definition, 86
 - tardive akathisia, 106–12
- indalpine, 103
- informed consent, 289–91
- insomnia
 - and periodic leg movements of sleep, 313
 - and restless legs syndrome, 300–1
- instrumental methods, 190–5
- intentional movements, 134–5, 319
 - akathisia, 134–5, 319

- restless legs syndrome, 319
- intramuscular neuroleptics, 121, 215
- intravenous neuroleptics, 121
- Involuntary Movement and Extrapyrarnidal Scale, 198–9
- involuntary movements, 134–5
 - activating task suppression of, 133–4
 - dyskinesia vs akathisia, 67, 172
 - restless legs syndrome, 302, 320
 - vs akathisia, 320
 - vs voluntary movements, debate, 134–5
- iron
 - blood levels, 244, 246
 - distribution and function, 217–19
- iron deficiency
 - and akathisia, 218–20, 244, 246
 - jitteriness predisposition, 35
 - pseudoakathisia patients, 246
 - restless legs syndrome, 297–8, 326
 - treatment, 253, 326
- jitteriness, 34–5
 - definition, 29
 - differential diagnosis, 147–8
 - noradrenergic activity increase, 35, 234
 - and tricyclic antidepressants, 18, 24, 29, 34–5
- kathisophobia, 5
- late-onset akathisia, *see* tardive akathisia
- leg cramps, 316
- leg movements
 - acute akathisia sign, 131–3, 168
 - pathogenesis, 243
 - tardive/chronic akathisia, 160–2, 166–8
 - and tremor, 138
 - variability, actigraphy, 139–40
- legal issues, 289–91
- Leige school, 10
- length of drug treatment, *see* duration of neuroleptic treatment
- limb–truncal dyskinesia
 - acute akathisia relationship, 143
 - age factors, 156–7
 - and chronic akathisia, 171–2
- lipophilic β -antagonists, 233, 269–72
- lithium
 - acute akathisia cause, 105
 - in restlessness/agitation, 45
- lorazepam
 - acute akathisia treatment, 273–4
 - tardive akathisia treatment, 286
- loxapine, receptor affinities, 213
- lying position, 168–9
 - acute akathisia, 132–3, 162
 - tardive/chronic akathisia, 161–2, 168–9
 - subjective report, 168
- malingering, differential diagnosis, 148, 179
- mania, and restlessness, 22
- mannerisms, differential diagnosis, 149
- marching in place, 167, 302
- masked tardive dyskinesia, 83
- massive myoclonic jerks, 314
- measurement, 188–209, 351
- melancholia, psychomotor agitation, 18, 21, 29
- melanocyte-stimulating hormone, 324
- mental retardation, and akathisia, 115–16
- Mental State Rating Schedule, 40
- ‘mesencephalic locomotor region’, 233–4
- mesocortical dopamine system, 224–6, 229–32, 242
- mesolimbic dopamine system, 229–32
- methadone, 334, 337
- methixen, 258
- methoxy-4-hydroxyphenyl glycol, 234
- methysergide
 - acute akathisia role, 98, 103
 - serotonin receptor antagonism, 235
- metoclopramide
 - acute akathisia role, 97, 100–1
 - tardive akathisia role, 109
- metoprolol
 - acute akathisia treatment, 269–70, 272
 - as challenge, 285
 - mechanism of action, 233
 - pharmacological characteristics, 268
- MHPG levels, 234
- mianserin, 103–4
- microvibration, 194
- Mini-Motionlogger, 194
- ‘mixed affective state’, 22
- MK-801, 238
- Modified Rogers Scale, 38
- molindone, receptor affinities, 213
- monoakathisia, 186
- monoamine oxidase inhibitors, 35
- motion analysis systems, 193
- motoneurone dissociation, 324
- motor features; *see also* objective akathisia
 - in acute akathisia, 130–4, 138–41, 162
 - activating task suppression of, 133–4
 - akathisia symptom component, 13

- motor features (*cont.*)
 and differential diagnosis, 144–5
 identifying signs, 130–3
 mesocortical dopamine hypothesis, 231
 in restless legs syndrome, 301–6
 vs drug-induced akathisia, 319
 sensory symptom relationship, 306–7
 in tardive/chronic akathisia, 162, 165–9
 variability, 138–41, 169–70
- motor tics
 and supplementary motor area, PET, 231
 voluntary–involuntary debate, 134–5
- movement, *see* motor features
- movement index, 313
- moving toes syndrome, 296
- MS–E – Mood Scales, Elderly, 41
- muscarinic receptors, 258
- muscular pain–fasciculation syndrome, 296, 315
- myelopathy, 309
- myoclonic jerks
 and acute akathisia, 135–7
 in awake state, 305
 classification, 295–6
 clonazepam effect, 333–4
 in restless legs syndrome, 302–3
 and tardive/chronic akathisia, 162, 169
- myoclonic movements
 and acute akathisia, 135–7
 differential diagnosis, 150
- myokymia, 315–16
- nadolol, 233, 267–9, 272
- naloxone, 323, 336
- narcolepsy, 313
- negative schizophrenic symptoms
 and pseudoakathisia, 246
 and tardive akathisia distress, 162, 176–8, 246
- negligence, 289–90
- neurasthenia, 358
- neuroleptic dosage
 acute akathisia incidence, 89, 90, 94, 214, 216
 differential diagnosis use, 145
 increments of, 252
 modification as treatment strategy, 252
 and neuroleptic-induced dysphoria, 53–4
 as risk factor, 214–16, 252
- neuroleptic-induced akathisia, *see* acute akathisia; chronic akathisia; tardive akathisia
- neuroleptic-induced dysphoria, 47–59
 akathisia distinction, 55, 146
 animal model utility, 57–9
 and anxiety/derealization, 49–50
 biochemical basis, 57–9
 and depression, 52–3
 description of, 47–8
 dosage effects, 53–4
 emotion-induced defecation model, 58–9
 and extrapyramidal side effects, 54–5
 longitudinal course, 56–7
 noncompliance reason, 49
 as outcome predictor, 57
 personality factors, 55–6
 as placebo response, 55
- neurological examination, 309
- neuropsychological deficits, 246
- neuroticism, 34
- nicotine, 220–1
- nicotine withdrawal, 25, 221
- nigrostriatal dopamine system, 228–9
- NMDA antagonists, 238
- nocturnal leg cramps, 316
- nocturnal myoclonus
 and akathisia, 136
 arousal in, 305
 classification, 295–6
 clonazepam treatment, 333
 differential diagnosis, 311–13
 motor phenomena, 304–5
- noncompliance, *see* drug compliance
- nootropic drugs, 277
- noradrenergic mechanisms
 acute akathisia, 232–4, 241–2
 restless legs syndrome, 324
 tardive akathisia, 248
- norepinephrine, 232–4, 248
- NREM sleep, 304
- objective akathisia, 176–8; *see also* motor features
 and akathisia diagnosis, 74–5
 conceptual aspects, 176–8
 identifying features, 65–6, 124–5, 130–3
 and negative schizophrenic symptoms, 246
 prevalence in tardive akathisia, 107–8, 111–12
 and tardive/chronic akathisia, 160–2, 176–8
- oestrogen/antidepressant combination
 acute akathisia role, 98, 103
 mechanism of action, 213
- ondansetron, 236

- onset of symptoms, 121
 - akathisia subtypes, 78
 - overview, 121
 - tardive/chronic akathisia, 157–8
- opiates
 - restless legs syndrome treatment, 334, 336–7
 - tardive/chronic akathisia treatment, 287
- opioid system, 238, 249; *see also* endogenous opioids
- opioid withdrawal, restlessness, 25
- Oppenheim, Hermann, 5, 5n1
- oral–buccal–lingual–facial dyskinesia
 - age factors, 156–7
 - akathisia distinction, 67
 - as subsyndrome, 173–4
- organic akathisia, 181, 289, 350–1
- orofacial dyskinesia
 - acute akathisia relationship, 143
 - in chronic/tardive akathisia, 171
 - spontaneous appearance, 174
 - tardive dyskinesia subsyndrome, 173–4
- orphenadrine HCl, 258
- oxycodone, 334, 336–7
- oxypertine, 285–6
- pain, and restless legs syndrome, 300
- painful legs and moving toes syndrome, 314–15
- painful sensory symptoms, and neuroleptics, 51–2
- panic disorder, and jitteriness, 34–5
- paradoxical drug reactions, 8, 11–12, 125–6, 319
- parenteral neuroleptic administration, 215, 252
- paresthesiae
 - akathisia versus restless legs syndrome, 316, 319
 - L-dopa effect, 328
- Paris school, 9–10
- Parkinson's disease
 - akathisia association, 15–16, 182–4
 - clinical features, 182–4
 - restless legs syndrome, 297–8
- paroxetine, 102–3
- partial gastrectomy, 297–8
- periodic leg movements of sleep
 - and akathisia, 136
 - baclofen treatment, 339–40
 - classification, 296
 - circadian influences, 325
 - clonazepam treatment, 333–4
 - differential diagnosis, 311–13
 - L-dopa treatment, 328
 - genetics, 308–9
 - motor phenomena, 304–5
 - sleep disturbance, 307–8
- peripheral neuropathy, 321
- peripheral vascular disorders, 321–2
- personality traits
 - and fidgetiness, 33–4
 - restlessness predisposition, 21
- pharmacologic challenge, and diagnosis, 79, 145
- phencyclidine, 24
- phenelzine, and jitteriness, 35
- phenoxybenzamine, 285
- physostigmine challenge, 283
- piezoelectric device, *see* actigraphy
- pimozide
 - separation anxiety syndrome, 50–1
 - as treatment alternative, 253
- pindolol, 268, 270, 272
- piracetam, 277
- piribedil, 330, 332
- placebo effect, and akathisia, 141
- plasma neuroleptic levels, 216
- polysomnography, 193–4
 - and cholinergic mechanisms, 237
 - methodology, 193–4
 - nocturnal myoclonus assessment, 136, 194
 - restless legs syndrome, 302–3, 307
- positron emission tomography
 - D₂ receptor, 228
 - supplementary motor area, 231
- postencephalitic parkinsonism, 15–16, 181–2
- postpsychotic depression, 52
- posture, and acute akathisia, 131–2, 168
- prefrontal cortex, 231, 240–2
- pregnancy, and restless legs syndrome, 297
- prevalence
 - acute akathisia, 88–105
 - definition, 86
 - restless legs syndrome, 296–7
 - tardive akathisia, 106–12
- Prince Henry Hospital Akathisia Scale, 360–2
 - development and reliability, 202
 - factor analysis, 204–6
 - interrater reliability, 207–8
 - validity, 206–8
- probable akathisia, 177
- procyclidine
 - acute akathisia treatment, 254

- procyclidine (*cont.*)
 pharmacokinetics, 258–9
 relative potency, 257–8
 tardive akathisia treatment, 282–3
- prophylaxis, anticholinergic drugs, 257
- propoxyphene, 287, 334, 336–7
- propranolol
 acute akathisia treatment, 259–67
 guidelines, 279
 in agitation and aggression, 45
 benztropine comparative efficacy, 266–7
 diagnostic use, 145
 dosage and duration of treatment, 266
 mechanism of action, 233
 pharmacological characteristics, 268
 and restless legs syndrome, 338, 340
 tardive akathisia treatment, 285
- propranolol challenge, 265
- pseudoakathisia, 176–8
 age factors, 156
 clinical features, 160–2
 conceptual aspects, 176–8
 history of term, 75
 incidence, 107–8
 iron levels, 246
 and negative schizophrenia symptoms, 246
 neuropsychological deficits, 246
 pseudodementia parallel, 75
 typology, 14–15, 83
- pseudodementia, 15
 pseudoakathisia parallel, 75
- psychomotor agitation, *see* agitation of depression
- psychomotor retardation, 29
- psychosis exacerbation, 125–7, 163–4
- psychostimulants, *see* amphetamines
- psychotic agitation, 146
- psychotic disorders, and restlessness, 22
- quadriceps muscle, 304
- racial factors, acute akathisia, 119–20
- raclopride, 100
- Rating Scale for Extrapryramidal Side Effects, 93
- rating scales, 196–208
 advantages and disadvantages, 196–7
 akathisia, 196–308
 restlessness, 37–42
- reactive depression, 30
- receiver operating characteristic analysis, 68–74, 76–7
- REM latency, 307
- REM sleep
 in akathisia, 237
 and periodic leg movements in sleep, 304, 307–8
- remission, and akathisia, 179–80
- remoxipride
 acute akathisia role, 97, 99–100
 as treatment alternative, 253
- renal failure, 297–8, 310
- reserpine, 285–6, 288
- respiratory dyskinesia, 167–8
- restiveness, 19, 29
- restless legs syndrome, 353
 aetiopathogenesis, 322–5
 akathisia differential diagnosis, 316–21
 benzodiazepines in, 330, 333–5
 carbamazepine in, 338, 340
 clinical features, 295–325
 clonidine in, 336
 course, 309–10
 diagnosis, 310–22
 diagnostic criteria, 311
 dopaminergic drugs in, 327–32
 drug-induced akathisia distinction, 316–21
 Ekblom's early description of, 6–7
 epidemiology, 296–7
 genetics, 308–9
 idiopathic vs symptomatic, 310–1
 motor features, 301–7, 319
 vs drug-induced akathisia, 319
 sensory symptom relationship, 306–7
 and neuroleptic era, 8–9
 opioid drugs in, 334, 336
 pathophysiology, 295–325
 sleep disturbance, 307–8
 subjective features, 299–301
 treatment, 326–41
 typology, 16
- restless red legs syndrome, 296, 321
- restlessness
 in acute akathisia, 122–3, 162
 aetiology, 19–21
 and affective disorders, 21–2
 anatomy, 18–46
 in childhood disorders, 22–3, 32
 clinical manifestations, 27–35, 346
 definition, 18–19, 29, 35–6, 346
 and dementia, 25–6
 drug-induced forms, 23–5
 drug therapy, 43–5
 and head injury, 26–7

- measurement scales, 37–42
- motor and mental components, 28, 346
- and Parkinson's disease, 183–4
- pathophysiology, 36
- personality trait predisposition, 21
- and restless legs syndrome, 301–2
- in tardive/chronic akathisia, 159–60, 162, 165–6
- treatment, 42–5
- rigidity, diagnostic value, 79
- risperidone
 - akathisia incidence, 101
 - as treatment alternative, 253
- ritanserin
 - acute akathisia treatment, 276–7
 - 5HT₂ antagonism, 235–6
- rocking movements
 - acute akathisia sign, 131–2
 - and restless legs syndrome, 302
 - and tardive/chronic akathisia, 166–7
- Rogers Scale of Motor Disorder, Modified, 38
- roxindole, 101
- Rutter Scale, 39

- savoxepine, 101
- schizophrenia
 - akathisia distress, 176–8
 - akathisia epidemiology, 120
- school avoidance/phobia, 50–1
- scopolamine, and restlessness, 25
- SDZ HDC912, 101
- segmental myoclonus, 136, 138
- Self-Rating Depression Scale, 93
- sensorimotor neuropathy, and restlessness, 27
- sensory tics, 134–5
- separation anxiety syndrome, 50–1
- serial 7s task, 133, 201
- serotonergic function, 235–6
 - akathisia mechanisms, 235–6, 241–2
 - animal models, 226–7
 - restless legs syndrome, 324
- serotonin antagonists, 98, 103
- serotonin receptors, 235–6
- serotonin reuptake inhibitors
 - acute akathisia role, 98, 102–3
 - akathisia mechanism of action, 235–6
 - restlessness association, 24
 - and suicidal ideation, 130
- serotonin syndrome
 - animal model, 226–7
 - motor activity, 24
- sertindole, 101
- sertraline, 95, 102–3
- sex differences
 - acute akathisia, 119
 - restless legs syndrome, 299
 - tardive/chronic akathisia, 157
- sexual cravings, 130
- Sicard, Jean Athanse, 5, 5n3
- sitting position symptoms, 168–9
 - acute akathisia, 131–3, 162
 - subjective distress, 140, 168
 - tardive/chronic akathisia, 160, 162, 166–9
- sleep
 - akathisia amelioration, 139–40
 - and cholinergic mechanisms, 237
 - myoclonic movements, 136–7
- sleep disorders
 - and periodic leg movements of sleep, 313
 - restless legs syndrome, 300–1, 307–8, 320
 - vs drug-induced akathisia, 320
- sleep latency, 307
- sleep starts, 314
- 'sleeping sickness', 181
- slow-wave sleep, 237
- smoking, 220–1
- Social Behaviour Schedule, 37–8
- sodium valproate, 238, 277
- soleus muscle, 204
- sotalol, 233, 267–9, 272
- spinal mechanisms, restless legs syndrome, 324–5
- St. Hans Rating Scale, 196
- standing position, 168–9
 - acute akathisia movements, 131–3, 162
 - subjective distress, 140, 168
 - tardive/chronic akathisia, 161–2, 166–9
- stereotypies
 - differential diagnosis, 149
 - in tardive akathisia, 168, 177
- stimulants, *see* amphetamines
- strain-gauge measures, 191–2
 - evaluation, 191–2
 - leg tremor, 138
 - tardive akathisia, 170
- stress
 - dopamine systems, akathisia worsening, 232
 - and restless legs syndrome, 301
 - and restlessness, 20–1
- striatal–pallidal–thalamic–cortical loop, 240–2
- subjective akathisia, 176–8
 - and akathisia diagnosis, 74–5
 - animal models, 224

- subjective akathisia (*cont.*)
 conceptual aspects, 176–8
 identification of, 65
 mesocortical dopamine hypothesis, 231
 and negative schizophrenic symptoms,
 176–7
 as outstanding akathisia feature, 122
 prevalence in tardive akathisia, 107–8,
 111–2
 in tardive/chronic akathisia, 158–62, 176–8
 substantia nigra pars reticulata, 239–42
 subthalamic abscess, 185–6
 subthalamic nucleus, 239–41
 Suggested Immobilization Test, 305, 309
 suicide
 akathisia association, 12, 129–30
 and fluoxetine-induced restlessness, 130
 sulcal prominence, 187
 sulpiride, 97, 100
 ‘sundowning’ phenomenon, 31–2
 supersensitivity psychosis, 163–4
 supplementary motor area, 231
 Symbol Digits Modalities Test, 245–6
 symptomatic restless legs syndrome, 310–1
- tardive akathisia
 aetiology, 243–6
 age factors, 156–7, 180
 anticholinergic drug treatment, 282–7
 behavioural analogues, 162–5
 characteristic symptoms, 13–14
 chronic akathisia relationship, 154–5
 clinical characteristics, 13–14, 158–80
 clozapine treatment, 282
 diagnostic criteria, 74, 76–8, 81–3
 differential diagnosis, 178–9
 evidence for syndrome, 152–4
 incidence and prevalence, 106–12
 movement pattern, 67
 natural history, 179–80
 objective (motor) features, 165–72, 176–8
 onset, 78, 157–8
 operational definition, 78
 organic vulnerability, 249–50
 pathogenesis, 247–50, 351–2
 pharmacological profile, 154
 reduced distress in, 159, 162
 research diagnostic criteria, 81–2
 risk, 179–80
 sex ratio, 157
 tardive dyskinesia overlap, 170–5, 350
 treatment, 279–88, 352–3
 guidelines, 284, 288
 typology, 13–15, 349–50
 variability, 169–70
- tardive dyskinesia
 acute akathisia as risk factor, 143–4
 akathisia distinction, 67, 170–5
 characteristic symptoms, 13–14
 pathophysiology, 174
 pharmacological response, 174–5
 primacy argument, 172–3
 subsyndromes, 173–4
 tardive akathisia overlap, 170–5
 typology, 13–15
- tardive dysmetria, 164–5
 tardive dysphrenia, 14
 tardive dystonia, 171
 tasikinesia, 5
 teeth grinding, 34
 telangiectasia, 321–2
 tergruride, 101
 terminal restlessness, 25, 29
 tetrabenazine, 285, 288
- thioridazine
 receptor affinities, 213
 relative safety, 10
- thiothixine
 acute akathisia incidence, 89
 receptor affinities, 213
- thiothixine challenge, 89
 three-dimensional motion analysis, 193
 tibialis anterior muscle, 304
- tics
 differential diagnosis, 150–1
 and supplementary motor area, PET, 231
 voluntary–involuntary debate, 134–5
- timolol, 268
 tobacco withdrawal, 38
- toe movements
 acute akathisia, 136, 162
 tardive/chronic akathisia, 160, 162
 and tremor, 137
- tort actions, 289–90
- Tourette’s syndrome
 akathisia epidemiology, 114–15
 voluntary versus involuntary debate, 134
- transient tardive akathisia, 83
- tremor, 137–8
 acute akathisia correlation, 137, 142
 differential diagnosis, 149
 and neuroleptic-induced dysphoria, 54–5
 strain-gauge measures, 138
 in tardive/chronic akathisia, 162, 169

- tricyclic antidepressants
 - acute akathisia treatment, 277
 - jitteriness cause, panic patients, 34–5
- tricyclic-induced akathisia, 24
 - epidemiology, 98, 103
 - mechanism of action, 213, 234
- trifluoperazine, 213
- trihexyphenidyl HCl, 258, 283
- triperidol, 10
- truncal movements
 - acute akathisia sign, 131–2
 - chronic akathisia sign, 166
 - and tardive akathisia, 171–2
 - tardive dyskinesia subsyndrome, 173–4
- L-tryptophan
 - akathisia improvement, 235
 - restless legs syndrome treatment, 339–40
- twins, restless legs syndrome, 308

- ultrasound transducers, 192–3
- unilateral akathisia, 68, 186
- urea nitrogen, 310

- valproate, 238, 277
- varicose veins, 321
- ventral tegmental area, 224, 233, 240
- ventricle–brain ratio, 187
- videotape ratings, 111, 167, 195–6
- violence, and acute akathisia, 12, 128

- visual analogue ratings, 198–9
- vocal tics
 - and supplementary motor area, PET, 231
 - voluntary–involuntary debate, 134–5
- voluntary movements
 - akathisia distinctive quality, 67, 172, 177
 - dyskinesia versus akathisia, 172
 - vs involuntary movements, debate, 134–5
- VTA syndrome, 224–6

- walking abnormalities, 131–2, 161–2
 - acute akathisia, 131–2
 - chronic/tardive akathisia, 165–6
- WATSMART motion analysis system, 193
- Willis, Thomas, 4, 3n1
- Wilson, Samuel Alexander Kinnier, 6, 6n4
- withdrawal akathisia
 - aetiology, 243–6
 - epidemiology, 112–14
 - onset, 78
 - operational definition, 78
 - research diagnostic criteria, 81, 83
 - treatment, 288–9
- Withdrawal Questionnaire, 38
- women
 - acute akathisia, 119
 - tardive/chronic akathisia, 157
- yen sleep, 25